CNS Pharmaceuticals, Inc. (NasdaqCM: CNSP)
Health Care · Pharmaceuticals · US
$6.29
+7.89% today · -10.9% 1Y
CNS Pharmaceuticals, Inc. (NasdaqCM: CNSP) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.52M and employs 8 people.
Over the last twelve months the share price has lost 10.9%, trading between 1.90 and 10.59.
Tweenvest scores CNS Pharmaceuticals, Inc. across four factors: quality 26/100. Its strongest factor is quality.
CNSP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.52M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -7.66
- Dividend yield
- —
- Beta (5Y)
- 0.98
- 52-week high
- $10.59
- 52-week low
- $1.90
- Avg volume (3M)
- —
- Shares outstanding
- 1.46M
- Employees
- 8
- Next earnings
- —
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
- ISIN
- US18978H5081
- Founded
- 2017
- Listed since
- Nov 8, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | 0.00% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.18 | +0.01% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.24 | -0.13% |
| Roche Holding AGSWX: ROP | $371.62B | CHF370.90 | -0.78% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £123.18 | -1.27% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.52 | -0.18% |
Figures last refreshed Aug 18, 2026.